GLP-1 Peptides (Semaglutide)
WellnessAlso known as: Semaglutide, Tirzepatide, Liraglutide, GLP-1 Receptor Agonists
Well-StudiedWhat is GLP-1 Peptides (Semaglutide)?
Prescription-only weight management peptides including Ozempic, Wegovy, and Mounjaro. The most clinically proven class of peptides for obesity and type 2 diabetes management. PRESCRIPTION ONLY.
How it works
Mimic the GLP-1 (glucagon-like peptide-1) hormone to activate GLP-1 receptors, suppressing appetite via hypothalamic signaling, slowing gastric emptying to increase satiety, and improving insulin sensitivity and glucose regulation.
What marketers claim
- ▸effortless weight loss with no lifestyle changes needed
- ▸cures obesity permanently
- ▸no significant side effects
- ▸works the same for everyone
What evidence supports
- ✓large-scale clinical trials demonstrate 15–20% body weight reduction
- ✓FDA-approved for obesity (BMI 30+) and type 2 diabetes management
- ✓cardiovascular outcome benefits documented in major trials
- ✓most clinically substantiated weight-loss intervention available
Research evidence
Key studies on GLP-1 Peptides (Semaglutide), summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
STEP 1: Semaglutide 2.4mg once-weekly for weight management
Finding: Participants receiving semaglutide 2.4mg lost an average of 14.9% of body weight at 68 weeks, compared to 2.4% in the placebo group. Over a third of participants lost more than 20% body weight.
Limitation: High dropout rate in the semaglutide group (~7%). Gastrointestinal side effects were common. Weight regain was observed after discontinuation in follow-up studies.
SELECT: Semaglutide cardiovascular outcomes trial
Finding: Semaglutide reduced major adverse cardiovascular events by 20% compared to placebo over a mean follow-up of 40 months.
Limitation: Study population had pre-existing cardiovascular disease, so results may not generalize to lower-risk populations.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1-4
Dose escalation phase (0.25mg). Appetite reduction begins. Nausea and GI side effects most common during this period.
Month 2-3
Dose increases to therapeutic range. Significant appetite suppression. Average 5-8% body weight loss by month 3.
Month 4-8
Full therapeutic dose (2.4mg). Average 10-15% body weight loss. GI side effects typically stabilize.
Month 12-16
STEP trial average: 15-17% body weight loss. Cardiovascular risk markers improve. Weight loss plateaus.
Safety notes & concerns
Full safety guide →- ⚠prescription only — not available or appropriate without physician oversight
- ⚠significant GI side effects common: nausea, vomiting, diarrhea, constipation
- ⚠potential muscle mass loss without adequate protein intake and resistance training
- ⚠weight typically returns if medication is stopped without lifestyle changes
- ⚠cost is $1,000+ per month without insurance coverage
- ⚠compounded versions may be unregulated and of unknown purity
- ⚠rare but serious risk of pancreatitis
Pairs well with
Use caution with
Frequently asked questions
Can I get semaglutide without a prescription?
No. Semaglutide (Wegovy, Ozempic) is a prescription-only medication that requires a physician assessment, diagnosis, and ongoing monitoring. Compounded versions sold without a prescription are unregulated and potentially unsafe.
Will I regain weight if I stop taking semaglutide?
Studies show that most people regain a significant portion of lost weight after discontinuing semaglutide if lifestyle changes are not maintained. The STEP 1 extension trial found approximately two-thirds of weight loss was regained within a year of stopping. This is why concurrent diet, exercise, and behavioral changes are essential.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is approved for type 2 diabetes (max 2mg dose), while Wegovy is approved for chronic weight management (2.4mg dose). The active ingredient is identical — the difference is the approved indication and dosing.
Products containing GLP-1 Peptides (Semaglutide)
Novo Nordisk
Wegovy (Semaglutide 2.4mg)
FDA-approved once-weekly injectable for chronic weight management; the most clinically proven peptide intervention for obesity with 15–17% average body weight reduction in STEP trials. PRESCRIPTION REQUIRED.
Eli Lilly
Mounjaro (Tirzepatide)
Dual GIP/GLP-1 receptor agonist — the first of its class, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). SURMOUNT trials showed up to 22% average body weight reduction. PRESCRIPTION REQUIRED.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
those following longevity research who pursue protocols with medical supervision
understanding as a cautionary example of peptide marketing vs evidence
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with GLP-1 Peptides (Semaglutide)
Last updated: 2025-03-01
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.